Hi-Tech Pharmacal
This article was originally published in The Tan Sheet
Executive Summary
Year-end sales rose to $56.4 mil., up 19% from the prior-year period, the company announces July 13. Net income for the fiscal year ended April 30 increased 15% to $6.6 mil., the Amityville, N.Y.-based company says. Although the Health Care Products division saw a 9% sales decrease, revenue for the DiabetiDerm line increased by 46%, which the firm attributes to strong sales of the line's foot cream containing L-Arginine. The company says it "intends to stay focused on branded products targeting the diabetes market and related areas, including podiatry and dermatology." Hi-Tech Pharmacal identified its increasing interest in products for diabetics last year (1"The Tan Sheet" Sept. 29, 2003, p. 10)...
You may also be interested in...
Hi-Tech Diabetic Products To Play Key Role In Firm’s Growth Strategy
Hi-Tech Pharmacal plans to build up its Health Care Products Division through a two-pronged approach involving launching new products aimed at diabetics and expanding distribution channels
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.